Latest Clinical Evidence in Extensive-Stage Small Cell Lung Cancer Treatment
Journal of the Advanced Practitioner in Oncology · 27.02.2026 · 17 (2)
DOI: 10.6004/jadpro.2026.17.2.10 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 27.02.2026. Verfasst von Stephanie McDonald und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Extensive-stage small cell lung cancer is an aggressive malignancy with historically poor survival outcomes. At JADPRO Live, presenters highlighted recent advances that are reshaping the management of this disease. Practical guidance focused on recognizing and managing oncologic emergencies, chemotherapy-related toxicities, immune-related adverse events, and novel toxicities associated with bispecific T-cell engagers, with a focus on patient and caregiver education.
Zitieren
APA
McDonald, S., MSN, FNP-BC, AOCNP, Castronovo, E., MSN, & AGNP-BC (2026). Latest Clinical Evidence in Extensive-Stage Small Cell Lung Cancer Treatment. Journal of the Advanced Practitioner in Oncology, 17(2). https://doi.org/10.6004/jadpro.2026.17.2.10
Vancouver
McDonald S, MSN, FNP-BC, AOCNP, Castronovo E, MSN, et al. Latest Clinical Evidence in Extensive-Stage Small Cell Lung Cancer Treatment. Journal of the Advanced Practitioner in Oncology. 2026;17(2). doi:10.6004/jadpro.2026.17.2.10
BibTeX
@article{McDonald2026,
author = {McDonald, Stephanie and MSN and FNP-BC and AOCNP and Castronovo, Elizabeth and MSN and AGNP-BC},
title = {Latest Clinical Evidence in Extensive-Stage Small Cell Lung Cancer Treatment},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2026},
volume = {17},
number = {2},
doi = {10.6004/jadpro.2026.17.2.10}
}
EUVIMED